Paloma Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-28,968
| Closed | -$5.28M | – | 1222 |
|
|
2024
Q1 | $5.28M | Buy |
28,968
+27,368
| +1,711% | +$4.72M | 0.28% | 85 |
|
|
2023
Q4 | $248K | Buy |
+1,600
| New | +$233K | 0.01% | 597 |
|
|
2023
Q3 | – | Sell |
-3,900
| Closed | -$525K | – | 701 |
|
|
2023
Q2 | $525K | Buy |
+3,900
| New | +$572K | 0.02% | 464 |
|
|
2022
Q4 | – | Sell |
-31,600
| Closed | -$4.24M | – | 886 |
|
|
2022
Q3 | $4.24M | Sell |
31,600
-40,400
| -56% | -$5.8M | 0.19% | 84 |
|
|
2022
Q2 | $11M | Buy |
72,000
+53,200
| +283% | +$8.13M | 0.39% | 30 |
|
|
2022
Q1 | $3.05M | Buy |
+18,800
| New | +$2.73M | 0.09% | 150 |
|
|
2021
Q4 | – | Sell |
-18,700
| Closed | -$2.02M | – | 1858 |
|
|
2021
Q3 | $2.02M | Buy |
18,700
+14,000
| +298% | +$1.6M | 0.05% | 231 |
|
|
2021
Q2 | $529K | Sell |
4,700
-11,300
| -71% | -$1.27M | 0.01% | 972 |
|
|
2021
Q1 | $1.73M | Buy |
+16,000
| New | +$1.71M | 0.04% | 466 |
|
|
2020
Q4 | – | Sell |
-8,200
| Closed | -$719K | – | 1581 |
|
|
2020
Q3 | $719K | Sell |
8,200
-31,800
| -80% | -$2.99M | 0.02% | 934 |
|
|
2020
Q2 | $3.93M | Buy |
40,000
+24,000
| +150% | +$2.11M | 0.07% | 381 |
|
|
2020
Q1 | $1.22M | Sell |
16,000
-17,700
| -53% | -$1.51M | 0.07% | 239 |
|
|
2019
Q4 | $2.98M | Buy |
+33,700
| New | +$2.8M | 0.04% | 426 |
|
|
2019
Q3 | – | Sell |
-8,800
| Closed | -$640K | – | 1897 |
|
|
2019
Q2 | $640K | Sell |
8,800
-44,800
| -84% | -$3.52M | 0.01% | 907 |
|
|
2019
Q1 | $4.32M | Buy |
+53,600
| New | +$4.38M | 0.11% | 207 |
|
|
2018
Q4 | – | Sell |
-41,400
| Closed | -$3.92M | – | 1217 |
|
|
2018
Q3 | $3.92M | Buy |
+41,400
| New | +$3.93M | 0.07% | 237 |
|
|
2018
Q1 | – | Sell |
-8,900
| Closed | -$861K | – | 1884 |
|
|
2017
Q4 | $861K | Sell |
8,900
-75,100
| -89% | -$7.08M | 0.01% | 1110 |
|
|
2017
Q3 | $7.46M | Hold |
84,000
| – | – | 0.1% | 179 |
|
|
2017
Q2 | $6.09M | Sell |
84,000
-126,200
| -60% | -$8.48M | 0.07% | 268 |
|
|
2017
Q1 | $13.7M | Sell |
210,200
-246,200
| -54% | -$15.5M | 0.16% | 85 |
|
|
2016
Q4 | $28.6M | Buy |
456,400
+440,400
| +2,753% | +$26.9M | 0.28% | 38 |
|
|
2016
Q3 | $1.01M | Sell |
16,000
-24,000
| -60% | -$1.55M | 0.01% | 1012 |
|
|
2016
Q2 | $2.48M | Hold |
40,000
| – | – | 0.03% | 584 |
|
|
2016
Q1 | $2.29M | Sell |
40,000
-11,000
| -22% | -$613K | 0.04% | 430 |
|
|
2015
Q4 | $3.02M | Buy |
+51,000
| New | +$2.94M | 0.08% | 229 |
|
|
2014
Q4 | – | Sell |
-20,000
| Closed | -$1.16M | – | 1129 |
|
|
2014
Q3 | $1.16M | Buy |
+20,000
| New | +$1.11M | 0.05% | 319 |
|
Other funds holding ABBV
Paloma Partners's ABBV Position: Q2 2025 in Review
Paloma Partners sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 5,775 shares — an estimated $1.21M sold.
Paloma Partners first reported a position in ABBV in Q3 2014 and held it in 35 quarters. The position peaked at $26M in Q2 2018. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.
- Paloma Partners reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
- Paloma Partners sold 5,775 AbbVie shares in Q2 2025, an estimated $1.21M.
- Paloma Partners first reported a position in AbbVie in Q3 2014 and held it in 35 quarters.
- Paloma Partners's AbbVie position peaked at $26M in Q2 2018.
- 3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.
Based on Paloma Partners's 13F filing for Q2 2025, filed 14 Aug 2025.